Diagnosis and treatment of acute myeloid leukemia. The updated 2018 Onkopedia Guideline

被引：0

作者：

Roellig, Christoph ^{[1
]}

机构：

[1] Univ Klinikum TU Dresden, Med Klin & Poliklin 1, Fetscherstr 74, D-01307 Dresden, Germany

来源：

INTERNIST | 2019年 / 60卷 / 03期

关键词：

Molecular targeted therapy; Risk; stratification; Midostaurin; Gemtuzumab; CPX-351; ACUTE MYELOGENOUS LEUKEMIA; MINIMAL RESIDUAL DISEASE; LOW-DOSE CYTARABINE; ADULT PATIENTS; GEMTUZUMAB OZOGAMICIN; COMPLETE REMISSION; NPM1; MUTATIONS; OLDER PATIENTS; RETINOIC ACID; REAL-WORLD;

D O I：

10.1007/s00108-019-0562-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In April 2018, an updated version of the previously published guidelines on acute myeloid leukemia (AML) from 2010 and 2017 was released. Arevision was necessary because of two positive aspects: First, new data and insights on risk stratification and monitoring, and second, the clinical development and approval of new agents. The modified genetic risk classification allows amore precise distinction of different diagnostic groups and consequently abetter matched post-remission treatment. The availability of new targeted drugs such as inhibitors turns genetic analyses from amere prognostic tool into an instrument for treatment decisions. Several recently approved agents expand the treatment options for AML and raise hope for an improved prognosis and cure in the future.

引用

页码：257 / 272

页数：16

共 38 条

[1] Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia [J].

Atallah, Ehab ;

Cortes, Jorge ;

O'Brien, Susan ;

Pierce, Sherry ;

Rios, Mary Beth ;

Estey, Elihu ;

Markman, Maurie ;

Keating, Michael ;

Freireich, Emil J. ;

Kantarjian, Hagop .

BLOOD, 2007, 110 (10) :3547-3551

[2] A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment [J].

Burnett, Alan K. ;

Milligan, Donald ;

Prentice, Archie G. ;

Goldstone, Anthony H. ;

McMullin, Mary F. ;

Hills, Robert K. ;

Wheatley, Keith .

CANCER, 2007, 109 (06) :1114-1124

[3] Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up [J].

Cabrero, Monica ;

Jabbour, Elias ;

Ravandi, Farhad ;

Bohannan, Zach ;

Pierce, Sherry ;

Kantarjian, Hagop M. ;

Garcia-Manero, Guillermo .

LEUKEMIA RESEARCH, 2015, 39 (05) :520-524

[4] Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study [J].

Castaigne, Sylvie ;

Pautas, Cecile ;

Terre, Christine ;

Raffoux, Emmanuel ;

Bordessoule, Dominique ;

Bastie, Jean-Noel ;

Legrand, Ollivier ;

Thomas, Xavier ;

Turlure, Pascal ;

Reman, Oumedaly ;

de Revel, Thierry ;

Gastaud, Lauris ;

de Gunzburg, Noemie ;

Contentin, Nathalie ;

Henry, Estelle ;

Marolleau, Jean-Pierre ;

Aljijakli, Ahmad ;

Rousselot, Philippe ;

Fenaux, Pierre ;

Preudhomme, Claude ;

Chevret, Sylvie ;

Dombret, Herve .

LANCET, 2012, 379 (9825) :1508-1516

[5] The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach [J].

Cornelissen, Jan J. ;

Gratwohl, Alois ;

Schlenk, Richard F. ;

Sierra, Jorge ;

Bornhaeuser, Martin ;

Juliusson, Gunnar ;

Racil, Zdenek ;

Rowe, Jacob M. ;

Russell, Nigel ;

Mohty, Mohamad ;

Lowenberg, Bob ;

Socie, Gerard ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (10) :579-590

[6]

Cortes JE., 2018, HEMASPHERE, V2, P1

[7] Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML [J].

DiNardo, C. D. ;

Stein, E. M. ;

de Botton, S. ;

Roboz, G. J. ;

Altman, J. K. ;

Mims, A. S. ;

Swords, R. ;

Collins, R. H. ;

Mannis, G. N. ;

Pollyea, D. A. ;

Donnellan, W. ;

Fathi, A. T. ;

Pigneux, A. ;

Erba, H. P. ;

Prince, G. T. ;

Stein, A. S. ;

Uy, G. L. ;

Foran, J. M. ;

Traer, E. ;

Stuart, R. K. ;

Arellano, M. L. ;

Slack, J. L. ;

Sekeres, M. A. ;

Willekens, C. ;

Choe, S. ;

Wang, H. ;

Zhang, V. ;

Yen, K. E. ;

Kapsalis, S. M. ;

Yang, H. ;

Dai, D. ;

Fan, B. ;

Goldwasser, M. ;

Liu, H. ;

Agresta, S. ;

Wu, B. ;

Attar, E. C. ;

Tallman, M. S. ;

Stone, R. M. ;

Kantarjian, H. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) :2386-2398

[8]

Dohner H, 2017, BLOOD, DOI [10.1182/blood-2016-08-733196.424, DOI 10.1182/BLOOD-2016-08-733196.424]

[9] International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts [J].

Dombret, Herve ;

Seymour, John F. ;

Butrym, Aleksandra ;

Wierzbowska, Agnieszka ;

Selleslag, Dominik ;

Jang, Jun Ho ;

Kumar, Rajat ;

Cavenagh, James ;

Schuh, Andre C. ;

Candoni, Anna ;

Recher, Christian ;

Sandhu, Irwindeep ;

Bernal del Castillo, Teresa ;

Al-Ali, Haifa Kathrin ;

Martinelli, Giovanni ;

Falantes, Jose ;

Noppeney, Richard ;

Stone, Richard M. ;

Minden, Mark D. ;

McIntyre, Heidi ;

Songer, Steve ;

Lucy, Lela M. ;

Beach, C. L. ;

Doehner, Hartmut .

BLOOD, 2015, 126 (03) :291-299

[10] Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review [J].

Eduardo Megias-Vericat, Juan ;

Martinez-Cuadron, David ;

Angel Sanz, Miguel ;

Montesinos, Pau .

ANNALS OF HEMATOLOGY, 2018, 97 (07) :1115-1153

← 1 2 3 4 →